In the United States, Western Europe and developing countries, type 2 diabetes is reaching epidemic proportions. It is now understood that the disease is part of a larger complex of disorders termed the "metabolic syndrome" -- insulin resistance, high blood pressure, cholesterol/lipid disorders, and type 2 diabetes -- that often leads to cardiovascular disease. Even with the availability of new classes of medicines, treatment of type 2 diabetes is difficult.
Earlier this year, San Diego biotech Novocell announced their success in converting human embryonic stem cells into insulin-producing beta cells, stopping type 1 diabetes in immune compromised mice. Even though the company is still a few years off from human clinical trials, the discovery rocked the diabetes world.
Earlier this month, 20,000 diabetes researchers and medical professionals converged on our "City by the Bay" to attend the ADA's 68th Annual Scientific Sessions. As host city, we were glad we arranged spectacular weather! Not only were our faculty and staff well represented at the seminars and workshops, we hosted a special event for former alumni and friends of the Diabetes Center.
Robert Lustig, MD is bombarded by media inquiries on a regular basis. What makes him so popular? Dr. Lustig is UCSF’s childhood obesity expert and a nationally recognized leader in the field of neuroendocrinology, with an emphasis on the regulation of energy balance by the central nervous system.
Kaveh Ashrafi, PhD and his colleagues including Supriya Srinivasan, PhD generated headlines earlier this month by challenging the theory that weight gain is mostly a consequence of feeding and physical activity. By working with the worm model C. elegans, they found that the brain chemical serotonin influences two separate pathways -- one for feeding and one for fat-burning.
A UCSF faculty member for over 20 years, Mike German, MD was awarded the prestigious David Rumbough Award for Scientific Excellence by the Juvenile Diabetes Research Foundation (JDRF). This award was established in 1974 by actress Dina Merrill, in honor of her late son, David. It is the highest honor JDRF awards, and is presented annually to researchers for outstanding achievement and commitment to diabetes research and for their service to JDRF.
As the U.S. continues to struggle with its war on weight, Sherri Shafer, RD, CDE continues to spread the word about proper medical nutrition therapy for adults and children with diabetes. Last month, Sherri was interviewed by Peter Jaret, health reporter for the New York Times on “A Nutritional Approach to Managing Diabetes”.
In January, former UCSF endocrinology fellow, Saleh Adi, MD, returned to UCSF – this time as the Associate Director of Clinical Pediatrics and the Director of Pediatric Diabetes Outpatient Services. Educated in Syria, Dr. Adi completed residencies at both the California Pacific Medical Center (CPMC) and at the Veteran’s Administration Hospital.
Diabetes Center faculty member Mark Anderson, MD, PhD was one of only thirteen physicians awarded the Clinical Scientist Award in Translational Research this year by the Burroughs Wellcome Fund. This program supports established physician-scientists dedicated to translational “bench to bedside” research by providing grants of $750,000 over five years.
In January, ABC Affiliate KGO of San Francisco interviewed UCSF pediatric endocrinologist Stephen Rosenthal, MD concerning a study to help assess how a dietary supplement might prevent type 1 diabetes in high-risk infants.
After being involved in diabetes and endocrine research at UCSF for nearly 40 years – a distinguished career that includes the breakthrough cloning of the growth hormone gene and first synthesis of growth hormone, the development of the UCSF Diabetes Center, the presidency of the Endocrine Society, and election to the prestigious National Academy of Sciences – you’d think John Baxter, MD would be ready to focus on his love of fishing. Instead of retirement, Dr.
Significant progress has been made in the past several years in improving the results of pancreatic islet transplantation for type 1 diabetics. Here at UCSF, we are very pleased with our success rate using a new enzyme that has helped to ensure islet viability through the transplant process.
Even the popular press is excited about recent developments involving anti-CD3, a potential type 1 therapy with strong ties to UCSF. In a recent issue of FORBES Magazine, senior editor Robert Langreth reveals the long history of anti-CD3 -- a monoclonal antibody that stops beta cell destruction.